PMI's intellectual property which forms the bases of our automated platforms was developed and licensed from BC Cancer Agency in Vancouver. The quantitative cytology system (ClearCyte)measures nuclear genetic material (DNA) of thousands of cell nuclei in a matter of few minutes and displays abnormal nuclei for review . This technology helps to provide highly informative early cancer detection tests including OralAdvance.

PMI Tech, with our dedicated team, works with partner laboratories around the world to improve the detection, localization and diagnosis of various types of cancer.